Important positive changes in Sarepta Therapeutics Inc (NASDAQ: SRPT) fundamentals have recently occurred: the consensus estimate for December, 2024 increased significantly, significant quarterly sales acceleration occurred, and the consensus estimate for December, 2025 increased significantly.
Important positive changes in Sarepta Therapeutics Inc (NASDAQ: SRPT) investment behavior have recently occurred: positive upside/downside volume developed.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
SRPT is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Sarepta Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Sarepta Therapeutics has a very high Power Rating of 89 and a very high Appreciation Score of 90, with the Highest Value Trend Rating the result.
Recent Price Action
Sarepta Therapeutics Inc (NASDAQ: SRPT) stock closed at $142.24 on 7/31/24 after a slight decline of -0.6%. However, unusually low trading volume at 50% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -3.7% during the last week.
Be the first to comment